Home›The Library›PT-141 / Bremelanotide
PT-141 (Bremelanotide)
Approved, yes — but for one specific, narrow indication in premenopausal women. Everything else it's commonly sold for (general libido enhancement, use in men, cosmetic tanning) sits outside both its approval and its actual trial data.
On this page
In brief
Should you care? Yes, especially if you've seen it marketed for uses beyond its label. This is a genuinely approved drug — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, specifically.The short version
- Real Phase 3 trials exist, and they're the basis for a real FDA approval.
- Nausea is common — reported in roughly 40% of treated women in the pivotal trials, a genuine tolerability issue.
- Off-label use in men, or above the approved dose, has none of the trial population or safety monitoring the approval was based on.
What it is
Bremelanotide (brand name Vyleesi, commonly sold under the research name PT-141) is a melanocortin receptor agonist — a cyclic peptide developed alongside, and related to, melanotan II, though it is a distinct, more selective molecule.
What the trial evidence shows
FDA approved Vyleesi in June 2019 based on the RECONNECT trials: two identical Phase 3, randomized, double-blind, placebo-controlled studies in premenopausal women with HSDD (Kingsberg et al., Obstet Gynecol 2019;134(5):899-908, DOI 10.1097/AOG.0000000000003500, PMID 31599840). Nausea was reported in roughly 40% of treated women versus about 1% on placebo, with a meaningful discontinuation rate tied to it — a real and substantial tolerability finding, not a footnote.
What it's approved for — and what it isn't
The approval covers acquired, generalized HSDD in premenopausal women, at a 1.75mg dose, taken as needed. It is not approved for men, and no trial evidence exists for using it that way. Vyleesi's label carries no boxed warning or REMS program, unlike flibanserin (Addyi), a competing HSDD drug — worth stating precisely rather than implying either drug is risk-free.
Off-label, above-label use is common
PT-141 is sold widely online, off-label, to men and often at doses above the approved 1.75mg — outside the population, dosing schedule and safety monitoring the trials and approval were actually based on.
Safety notes
Beyond the nausea rate, the label describes transient blood-pressure elevation as a mechanistic concern from melanocortin receptor agonism — a distinct safety point from the nausea finding, and worth knowing on its own terms rather than assuming "well-tolerated" applies across the board.
References
- Kingsberg et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials," Obstet Gynecol 2019;134(5):899-908, DOI 10.1097/AOG.0000000000003500, PMID 31599840.